Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21025LM" target="_blank" >RIV/61988987:17110/20:A21025LM - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/20:00115336 RIV/65269705:_____/20:00072661 RIV/00843989:_____/20:E0108383

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13358" target="_blank" >https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13358</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ejh.13358" target="_blank" >10.1111/ejh.13358</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients

Popis výsledku v původním jazyce

Objectives Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site-limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that is not site-limited, but equally challenging. Methods While majority of current data comes from short-term studies, we present a long-term study on blood-based MRD monitoring using tumor-specific cell-free DNA detection by ASO-qPCR. One hundred and twelve patients were enrolled into the study, but long-term sampling and analysis were feasible only in 45 patients. Results We found a significant correlation of quantity of tumor-specific cell-free DNA levels with clinically meaningful events [induction therapy (P = .004); ASCT (P = .012)]. Moreover, length of cfDNA fragments is associated with better treatment response of patients. Conclusions These results support the concept of tumor-specific cell-free DNA as a prognostic marker.

Název v anglickém jazyce

Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients

Popis výsledku anglicky

Objectives Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site-limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that is not site-limited, but equally challenging. Methods While majority of current data comes from short-term studies, we present a long-term study on blood-based MRD monitoring using tumor-specific cell-free DNA detection by ASO-qPCR. One hundred and twelve patients were enrolled into the study, but long-term sampling and analysis were feasible only in 45 patients. Results We found a significant correlation of quantity of tumor-specific cell-free DNA levels with clinically meaningful events [induction therapy (P = .004); ASCT (P = .012)]. Moreover, length of cfDNA fragments is associated with better treatment response of patients. Conclusions These results support the concept of tumor-specific cell-free DNA as a prognostic marker.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/NV17-29343A" target="_blank" >NV17-29343A: Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Haematology

ISSN

0902-4441

e-ISSN

1600-0609

Svazek periodika

104

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

190-197

Kód UT WoS článku

000503619400001

EID výsledku v databázi Scopus

—